fda warning letters compounding semaglutide news September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns – Partnership for Safe Medicines National Hispanic Medical Association |
Description
It would be irresponsible to write any of this without naming the tradeoffs honestly
Cell Metab 27(2):450460.e6
For patients prioritizing maximum weight loss, tirzepatide may be preferable
The most common adverse effects are gastrointestinal, including nausea, vomiting, diarrhea, constipation, and abdominal discomfort
InjectCos weight loss program includes ongoing support and progress tracking, with continued access to the care team between check-ins to help you stay engaged throughout the program
This combination creates a plateau where the dose that once worked no longer produces the same effect
